Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
BridgeBio disclosed new clinical trial data for its lead oncology programs (BBO-8520, BBO-11818, BBO-10203) and announced a strategic portfolio prioritization, deprioritizing certain programs (BBO-8520 in 1L NSCLC and BBO-10203 in breast cancer) while focusing capital on higher-probability opportunities. This is a material operational and strategic business event—the company is reallocating resources based on clinical progress and competitive landscape—but does not fit the specific categories of earnings release, M&A, impairment, or other named types. The disclosure includes encouraging efficacy data (75% ORR for BBO-8520 + pembrolizumab) and cash runway into 2028, both relevant to investor assessment of the company's prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-08
Item 8.01
The Company declared monthly distributions to shareholders across six classes of common stock and originated four new mortgage loans totaling approximately $233.9 million, including Self-Storage 5-Pack ($39.8M), Fort Worth Industrial ($26.5M), Dallas Office ($123.2M), and Atlanta Multifamily ($44.5M).
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 1.01
Amylyx entered into manufacturing and supply agreements with Bachem (definitive) and Polypeptide (term sheet) to secure long-term supply of avexitide drug substance for commercial use. While Item 1.01 typically covers M&A activity, these are strategic operational/supply agreements essential to the company's ability to commercialize its lead drug candidate, not acquisitions or dispositions. The agreements establish minimum purchase commitments beginning in 2028 and include a $30 million upfront fee to Polypeptide, making this a material operational milestone for a biopharmaceutical company dependent on third-party manufacturing.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
Evommune announced that its Phase 2b clinical trial of EVO756 in atopic dermatitis failed to meet primary and secondary endpoints across all doses studied. The company will cease development of EVO756 for atopic dermatitis but will continue evaluating EVO756 in migraine prophylaxis and advance its lead program EVO301 into Phase 2b for atopic dermatitis.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
EX-99.1
This press release announces a major customer win: selection by "one of the world's largest automotive groups" for a Level 3 autonomous driving radar program across multiple brands, with series-production deliveries scheduled to begin Q4 2027. While the disclosure does not fit the specific categories of M&A activity, debt issuance, or earnings results, it represents a material operational and commercial milestone—a significant new customer contract and program that would affect a reasonable investor's assessment of Arbe's commercialization progress and revenue prospects. The forward-looking statements acknowledge execution risks, but the selection itself is a discrete operational event warranting disclosure.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
EX-99.1
This press release announces Beamr's strategic partnership with VAST Data as a Technology Partner in the VAST Cosmos Community, with joint go-to-market initiatives and a product demonstration at IBC 2026. The disclosure describes a material business collaboration involving complementary video and data workflows, product integration, and joint commercialization efforts. While not a discrete M&A transaction, the partnership represents a significant operational and strategic business development that would affect a reasonable investor's assessment of the company's growth prospects and market positioning.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
EX-99.1
This press release announces Yale University IRB approval enabling patient recruitment for Parts B and C of Clearmind's Phase I/II CMND-100 clinical trial, following positive safety results from Part A. The disclosure is a material operational milestone for a clinical-stage biotech company—it represents regulatory clearance to advance a key clinical program at a leading academic medical center and directly enables acceleration of enrollment. While the event is clearly operational/clinical in nature, it does not fit the specific named categories (it is neither an earnings release, executive change, M&A activity, nor a discrete financial event), making `operational_other` the appropriate classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
EX-99.1
This press release announces two significant clinical development milestones for a clinical-stage biotech company: first patient dosed in Australia for AN4035 (initiating a global Phase I trial) and FDA IND clearance with "Study-May-Proceed" letter. These are material operational/regulatory achievements that advance the company's lead therapeutic candidate, but they do not fit the specific event-type categories (not earnings, M&A, exec changes, impairment, litigation, or other named types). The disclosure is clearly operational—a product development and regulatory milestone—making `operational_other` the appropriate classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
EX-99.1
Reitar announced execution of a non-binding memorandum of understanding (MOU) with ESR Group to explore smart logistics solutions and potential collaboration at ESR's Kwai Chung Logistics Centre. While the MOU is explicitly non-binding and contains no assurance of definitive agreement or implementation, the announcement describes a strategic partnership opportunity involving Reitar's core "Property + Logistics Technology" platform and ecosystem capabilities. This is a material operational/strategic development for a logistics technology company, though the non-binding nature and contingencies temper the certainty of materialization.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
EX-99.1
Scinai announced the conclusion of its option and license arrangements with PinCell regarding PC111 and a strategic refocusing of R&D resources toward its NanoAb platform and CDMO business. This is a material portfolio restructuring decision affecting the company's strategic direction and capital allocation, but does not fit neatly into specific event categories (not an M&A termination, not a workforce reduction, not a specific financial event). The decision to exit PC111 and reallocate resources is an operational/strategic business event that would affect a reasonable investor's assessment of the company's future prospects and capital deployment.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-08
Item 1.01
Bluejay Diagnostics entered into a Distribution, Co-Marketing & Strategic Partnership Agreement with Lovell Government Services on September 1, 2026, establishing exclusive and non-exclusive distribution rights for federal healthcare markets (VA, DoD, IHS). This material strategic partnership creates scalable commercial infrastructure for accessing the U.S. federal healthcare market—representing approximately $237 billion in combined budgets—contingent on FDA clearance.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 7.01
Suniva announced completion of an $835 million capital raise (debt and equity financing) to fund construction of a second major U.S. solar cell manufacturing facility in Laurens County, South Carolina, expanding capacity from 1 GW to 5.5 GW. While this involves capital raising and financing, the core disclosure centers on a material operational and strategic expansion—a new manufacturing facility with significant capacity growth and job creation. This is disclosed under Item 7.01 (Regulation FD Disclosure) as a press release and is material to investors assessing the combined SUNation-Suniva entity's operational scale and growth trajectory.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
EX-99.1
The press release announces Acco Group's receipt of a Corporate Service Provider (CSP) license from Singapore's ACRA and the launch of licensed CSP operations through its subsidiary Accolade IP (SG) PTE. LTD. This represents a material operational and strategic expansion into a new regulated service line in a key regional market. While not a discrete M&A transaction, debt issuance, or executive change, the licensed entry into a new service sector with significant addressable market opportunity (US$2.0 billion, 6.7% CAGR) constitutes a material operational milestone that would affect a reasonable investor's assessment of the company's growth trajectory and market positioning.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
EX-99.1
This news release reports completion of a summer drilling program at IsoEnergy's Larocque East project, with results showing widespread and elevated radioactivity intersections along the Hurricane South Trend. The disclosure details exploration results (10,159 m drilled in 26 holes, with 18 holes returning intervals above 350 cps threshold and 13 holes at 1,000 cps or greater), which are material operational/exploration milestones for a uranium exploration company. While not a discrete M&A, financing, or governance event, the successful expansion of drilling results and the company's characterization of these as "strongest radioactivity to date" represent material progress on the company's primary asset development objective.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
EX-99.1
This news release announces the maiden Mineral Resource estimate for Collective Mining's Apollo Deposit at its Guayabales Project in Colombia. The disclosure is a material operational milestone for an exploration-stage mining company — the first formal resource estimate for a flagship project represents a significant advancement in the property's development trajectory and would inform investor assessment of the company's exploration success and future value creation potential. While not fitting a discrete named event type, this is clearly an operational/strategic business milestone material to investors in a junior mining exploration company.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
EX-99.1
This news release announces Collective Mining's maiden Mineral Resource estimate for the Apollo deposit at its Guayabales Project in Colombia. The disclosure details a significant exploration milestone—37.0 Mt Indicated and 48.2 Mt Inferred at 2.17 and 1.83 g/t AuEq respectively—representing a material operational and strategic advancement for the company's flagship project. While not a discrete M&A transaction, debt issuance, or financial restatement, this resource estimate is a major operational milestone that would materially affect a reasonable investor's assessment of the company's asset base and development trajectory, particularly given management's stated intent to accelerate permitting and target an environmental license application in H2 2027.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 7.01
The disclosure announces commencement of cultivation activities at Grown Rogue's Minnesota facility following regulatory approval, with Phase I buildout details and expected first harvest timing. This is a material operational milestone for the company's geographic expansion strategy, but does not fit a specific named event type—it is neither a material contract, partnership, product launch, nor restructuring, but rather a significant operational achievement in the company's cultivation platform expansion. The event is clearly operational and material to investors assessing the company's execution on its Minnesota market entry.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
EX-99.1
Pampa Energía announces approval of its Fertilizer Project under Argentina's RIGI (Incentive Regime for Large Investments), with an estimated investment of approximately US$2.7 billion and capacity of 2.1 million metric tons of urea per year. This is a material operational and strategic milestone — a major capital project receiving government incentive qualification — but does not fit the specific categories of M&A activity, debt issuance, or other named event types; it is best classified as a significant operational/strategic development.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
Vale's 6-K discloses clarifications regarding media reports that the company has shelved its plans to conduct an IPO of Vale Base Metals, its base metals unit. While the company states no new corporate decision has been made and reiterates prior clarifications that no studies or decisions regarding a potential public offering were underway, the disclosure addresses a material strategic initiative (the potential spin-off/IPO of a significant business unit) that would affect investor assessment of the company's capital structure and strategic direction. This is an operational/strategic matter that does not fit the specific M&A or capital-raising categories but is clearly material to investors.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-08
Item 7.01
The disclosure centers on execution of a non-binding Letter of Intent with EthosEnergy O&M for operations and maintenance services of the Lufkin power facility, contingent on successful acquisition completion. This is a material operational/strategic milestone—identifying and securing a qualified O&M partner for a 55 MW facility supporting the Company's data center strategy—but does not fit the specific categories of M&A activity (the LOI is non-binding and the acquisition itself remains pending), debt issuance, or other named event types. The operational significance and materiality to investors evaluating the Company's ability to execute its Lufkin project strategy support classification as operational_other rather than a routine disclosure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
Lightbridge was selected for the U.S. Department of Energy's Launch Pad INL Program, a material operational and strategic milestone that accelerates the company's commercialization pathway for its advanced nuclear fuel technology. The program enables a two-pronged strategy (SHED facility under DOE authorization and LEFF under NRC licensing) that could accelerate time-to-market by several years, representing one of the most consequential milestones in the company's history.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Nova Minerals disclosed the arrival of approximately 500 tons of processing and refining equipment in Alaska as a significant milestone toward establishing its antimony production facility, funded by a $43.4 million Department of War award under the Defense Production Act. This represents material operational progress on a critical minerals project with national security implications and production targeted for 2027, disclosed via Item 7.01 (Regulation FD Disclosure) press release. While the event is clearly operational and strategic in nature, it does not fit neatly into a specific named category (not a contract, partnership, or regulatory milestone per se, but rather project development progress), making operational_other the most appropriate classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
EX-99.1
Pulsenmore announced completion of CE European registration for its Pulsenmore FC home ultrasound system for fertility monitoring, marking the company's second product authorized in Europe and first expansion beyond prenatal care into women's health. This is a material regulatory milestone enabling market entry across European markets, but does not fit discrete event categories (not M&A, not a financial result, not an executive change, not a restatement or impairment). The disclosure is clearly operational—a product regulatory approval and market expansion milestone—making operational_other the appropriate classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Soluna announced completion of Project Kati 1 (83 MW energized) and conditional Base Load classification from ERCOT for the full 166 MW campus. This represents a material operational milestone—the company delivered on its timeline, increased total operating capacity to 206 MW, and secured favorable grid interconnection status. While not a traditional M&A, earnings release, or governance event, this operational achievement materially advances the company's strategic capacity expansion and grid positioning.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-08
The filing's primary substantive disclosure is the termination of a Management Services Agreement with Ethereum Tower (Item 1.02) and replacement with a new advisory services agreement with American Validator LLC at a simplified 1.50% fee structure. While this involves a material contract change affecting the Company's Ethereum staking operations, it does not fit neatly into the specific financial or operational categories. The termination itself was not penalizing, and the new arrangement appears to be a routine operational restructuring of service provider relationships. Item 7.01 references an operational update press release announcing ETH holdings and staking metrics, which is promotional rather than disclosing a discrete material event. The contract restructuring is material to investors assessing operational efficiency but lacks the specificity of debt issuance, M&A, or other defined event types.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 7.01
HCW Biologics announced entry into an Exclusive Distribution Agreement with Akron Biotech for commercialization of HCW11-006 as a reagent for CAR-T cell manufacturing. This is a material strategic partnership and commercial milestone for a clinical-stage biopharmaceutical company, involving pre-payment commitments and distribution through an established network. While not a traditional M&A transaction, it represents a significant operational and commercial development that would affect a reasonable investor's assessment of the company's commercialization strategy and revenue prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
EX-99.1
The press release announces entry into a strategic partnership agreement with SANVO Fine Chemicals Group Limited, appointing SANVO as the sole supplier and exclusive manufacturer for mass production of BocaPCM-TES Panels in China. This is a material operational and strategic business event that affects the Company's manufacturing strategy, capital expenditure plans, and market expansion timeline, but does not constitute a discrete M&A transaction, debt issuance, or other specifically-named event type. The partnership eliminates capital investments in new production lines and allows the Company to focus on R&D and global expansion.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
EX-99.1
This press release announces SMX's unveiling of a four-layer Digital Material Passport Platform (DMPP) for plastics, representing a significant product launch and strategic milestone. The disclosure describes the company's new integrated platform connecting physical plastic marking, digital passports, market trading infrastructure, and circularity credits. While this is a material operational and strategic development for the company's business, it does not fit neatly into the specific event categories (it is not M&A, earnings, executive changes, debt issuance, or other defined types). The announcement of a major new product platform and the opening of a global client experience with free trials constitutes a material operational event that would affect a reasonable investor's assessment of the company's strategic direction and commercial prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
EX-99.1
Draganfly announced its selection as a Qualified Supplier under Canada's Defence Drone Initiative Marketplace across all five capability streams, effective August 28, 2026. This is a material operational and strategic milestone that establishes a pathway for significant government contract opportunities with the Canadian Armed Forces and Coast Guard within a $180 billion defence procurement program. The qualification across all five streams positions the company to compete for substantial future defence contracts, making this a material business development event that would affect a reasonable investor's assessment of the company's growth prospects and market access.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
EX-99.1
CLINUVEL announced completion of development of ZEROKIN™, a proprietary single-use administration device for subcutaneous drug delivery, with IP application submitted and plans to pursue FDA 510(k) registration and CE marking. This is a material operational and strategic milestone—a new product/technology platform—but does not fit the specific event categories (not an earnings release, M&A, executive change, impairment, or litigation). The disclosure reflects significant R&D progress and commercial strategy advancement that would affect investor assessment of the company's pipeline and competitive positioning.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-08
Item 1.01
StimCell Energetics entered into an Advisory Services Agreement with Stonegate Capital Markets on August 24, 2026, to identify and introduce prospective investors and strategic counterparties for potential transactions involving the Company's assets, debt, or equity securities. The engagement is a strategic advisory arrangement for capital-raising and M&A support on a best-efforts, non-exclusive basis with success-based compensation.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
X4 Pharmaceuticals announced a positive outcome from an FDA Type C Meeting regarding the 4WARD Phase 3 clinical trial for mavorixafor in chronic neutropenia. The FDA agreed to reduce the trial's sample size from 176 to 126 participants while maintaining statistical power for co-primary endpoints, and approved the proposed safety database for a potential supplemental new drug application. This is a material regulatory milestone affecting the clinical development pathway and timeline (enrollment expected by end-2026, topline data in H1 2028) for a key product candidate, making it a significant operational/strategic event for the company's pipeline, though it does not fit neatly into the specific event categories (not a restatement, impairment, covenant breach, or other defined type).
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
Harmony reports a fatal workplace incident at its Moab Khotsong mine on September 6, 2026, involving a seismicity-related loss of life. While the disclosure is primarily operational and safety-related rather than fitting a specific named category, it is material to investors as it reflects operational risk, potential regulatory consequences, and management's commitment to safety—factors that affect the registrant's ability to operate its mines safely and profitably. The incident triggers an investigation by the Department of Mineral and Petroleum Resources, adding regulatory dimension.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-08
Item 8.01
Strive announced a bitcoin purchase of 1,375 BTC at ~$79,281 per coin (totaling approximately $109 million) during August 31–September 4, 2026, along with updated holdings of cash, bitcoin, and equity securities. This represents a material capital deployment and treasury strategy execution that would affect investor assessment of the company's financial position and strategic direction, but does not fit neatly into debt issuance, M&A, impairment, or other specific financial categories. The disclosure is operational/strategic in nature—a treasury management and asset allocation decision—rather than a discrete financial event like a debt or equity issuance.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
Cycurion announced approximately $800,000 in annual contract spend across multiple new commercial engagements, including a pharmaceutical AI Center of Excellence engagement and a NACCHO award. This represents execution of the company's stated commercial expansion strategy into healthcare and life sciences. While not a single discrete operational event like a major contract or partnership, the announcement of multiple material commercial wins that advance the company's strategic direction and demonstrate market traction constitutes a material operational disclosure warranting investor attention.
View raw filing on EDGAR →
8-K
Operational Other
confidence 92%
filed 2026-09-08
Item 1.01
Quantinuum entered into a material definitive agreement with the U.S. Department of Commerce on September 4, 2026, securing up to $100 million in CHIPS Act funding for trapped-ion quantum computer manufacturing R&D. Under the agreement, the Department of Commerce received 2,369,528 shares of Class A common stock, representing a material capital infusion and equity issuance that affects the company's capital structure and strategic positioning in quantum computing.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-08
Item 8.01
Spyre announced positive Phase 2 SKYLINE trial topline data for SPY003 (anti-IL-23) in ulcerative colitis, demonstrating a statistically significant 10.0-point reduction in RHI score (p<0.0001) and clinical remission rates of 20%, meeting all key efficacy and safety objectives. This represents a material clinical development milestone and proof-of-concept for a key pipeline asset, advancing the company's combination strategy and strengthening its IBD program.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
This disclosure announces FDA approval of Etcamah (camizestrant) in combination with CDK4/6 inhibitors for first-line HR-positive breast cancer with emergent ESR1 mutations, based on positive Phase III SERENA-6 trial results showing 56% risk reduction in disease progression or death. While this is a significant regulatory and commercial milestone for AstraZeneca's oncology portfolio, it does not fit the specific event types of earnings_release, ma_activity, or other defined categories. It is a material operational/commercial event—a major product approval—that would affect investor assessment of the company's pipeline and market position, warranting operational_other classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
Guardian Metal's admission to the FTSE AIM 50 Index effective 21 September 2026 is a significant operational and market milestone. The press release emphasizes this as "an important milestone on the journey" and reflects the company's momentum in tungsten exploration and development. While not a discrete transaction (M&A, debt issuance, or earnings event), index inclusion materially enhances the company's market profile, liquidity, and visibility to institutional investors, affecting a reasonable investor's assessment of the registrant's strategic position and market standing.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
IQSTEL announced a strategic partnership with IDILIO TV to distribute premium microdrama content through its existing telecommunications operator relationships, targeting 40 million potential mobile users by Q2 2027 and 500,000 gross subscribers by year-end 2027. This is a material operational and strategic initiative leveraging the company's existing telecom infrastructure to enter a higher-margin digital content distribution business, supported by a $5 million seed round for IDILIO TV. While not a traditional M&A transaction, it represents a significant strategic pivot and new business line that would affect investor assessment of the company's growth strategy and revenue diversification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
EX-99.1
This news release announces Aris Mining's commencement of construction of a permanent bridge across the Puruni River in Guyana as an early infrastructure initiative supporting the Toroparu Gold Project. The bridge is a material operational milestone—it represents a significant capital commitment and infrastructure development that strengthens logistics access to a key project in the company's portfolio. While not a discrete event type like M&A or workforce reduction, it is clearly an operational/strategic business development that would affect a reasonable investor's assessment of project advancement and capital deployment.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
GRI Bio announced positive Phase 2a translational biomarker data from its GRI-0621 (oral tazarotene) study in idiopathic pulmonary fibrosis patients, demonstrating proof-of-concept across multiple mechanistic pillars (immune rebalancing, fibrolysis, lung repair, antitussive, GI-protection) and supporting advancement toward a pivotal Phase 2b/3 adaptive study.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
EX-99.1
This exhibit discloses the operational details and schedule for the discontinuation of Inter & Co's Level II Sponsored BDR Program on B3, approved by the Company's Board on January 26, 2026 and authorized by CVM Official Letter No. 81/2026 dated September 1, 2026. The disclosure outlines three alternatives for BDR holders (Receipt of Class A Shares on NASDAQ, Receipt of Level I Unsponsored BDRs, or automatic Sales Facility), with a 30-day Selection Period beginning September 17, 2026. This is a material operational and capital-structure event affecting the Company's listing and shareholder access to its securities, though it does not fit the specific categories of M&A, delisting risk, or other defined event types.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
Inhibrx announced positive Phase 2 clinical trial results for INBRX-106 in head and neck squamous cell carcinoma, demonstrating a 48.3% response rate versus 26.5% for the control arm, with particularly strong results in HPV+ patients (80.0% vs 33.3%). The company plans to expand the trial and pursue an accelerated regulatory pathway.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
EX-99.1
This press release discloses material progress on Mayfair Gold's exploration and development program at the Fenn-Gib Project, including completion of a 2026 summer geology program (mapping 95% of outcrops, 127 grab samples, 23 condemnation drill holes totalling 6,184 metres) and advancement of South Block targets toward drill-ready status for early 2027. The company is also building a comprehensive 3D geological and geochemical model to support mine development and exploration. While not a discrete M&A, financing, or governance event, this operational milestone—advancing a development-stage gold project toward construction (targeted 2028) and production (2030)—would materially affect a reasonable investor's assessment of the registrant's progress toward its stated development strategy and timeline.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-03
Item 8.01
Liquidia announced FDA Fast Track designation for YUTREPIA (treprostinil) inhalation powder for treatment of Raynaud's phenomenon associated with systemic sclerosis. This is a regulatory milestone that accelerates development and review timelines for a clinical-stage indication, representing material progress in the company's pipeline. While not a completed M&A transaction or earnings release, this operational/regulatory achievement would affect a reasonable investor's assessment of the company's development prospects and competitive position.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-03
Item 8.01
Milestone Pharmaceuticals announced China's NMPA approval of etripamil nasal spray for PSVT treatment, marking the first regulatory approval outside the United States. This is a material operational/regulatory milestone that triggers a $2.0 million payment and positions the company for up to $98 million in future milestone payments and royalties through its licensing partner Everest Medicines. While this is a significant product approval event, it does not fit neatly into the specific operational categories (workforce reduction, material contract, partnership) but represents a major regulatory and commercial milestone for the company's pipeline expansion.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-03
Item 1.01
NextCure entered into a Ninth Amendment to its lease agreement that accelerates termination of its laboratory and office space at 8000 Virginia Manor Road, Beltsville, Maryland, effective September 1, 2026, with a one-time termination fee of approximately $0.8 million and forfeiture of a $39,000 security deposit. This is a material operational event involving the early exit from a significant facility lease (approximately 29,864 rentable square feet), though it does not fit the specific categories of M&A activity, workforce reduction, or other named operational types. The materiality is supported by the substantial termination costs and the apparent strategic decision to vacate the premises.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-03
EX-99.1
This press release announces completion of the last patient visit in the NATiV3 Phase 3 clinical trial of lanifibranor for MASH treatment, with topline results expected in Q4 2026. This is a material clinical development milestone for a clinical-stage biopharmaceutical company whose lead product candidate is in pivotal Phase 3 testing. The event is operational/strategic (a key trial milestone) rather than a discrete financial, governance, or legal event, and does not fit the specific categories of earnings release, M&A, or other named types. The company has received FDA Breakthrough Therapy and Fast Track designations, and successful trial results could support regulatory submission and commercialization in 2027–2028, making this milestone material to investors assessing the company's pipeline progress and value.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-03
Item 7.01
Climb Bio disclosed positive Phase 1 trial results for CLYM116, an anti-APRIL monoclonal antibody, including a ~29-day half-life, >90% APRIL suppression, and favorable safety profile supporting every-12-week dosing. This is a material clinical development milestone for a lead pipeline asset, but does not constitute an earnings release (no financial results), M&A activity, or other specifically-defined event type. The disclosure is clearly operational—a significant clinical program update—rather than financial, governance, or legal in nature.
View raw filing on EDGAR →